Posted by Michael Wonder on 25 Aug 2022
Lynparza approved in Japan as adjuvant treatment for patients with BRCA mutated HER2 negative high-risk early breast cancer
25 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the adjuvant treatment of patients with BRCA mutated HER2 negative early breast cancer at high risk of recurrence.
